# Home Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/home-biosciences

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.homebiosciences.com
- Total disclosed funding: $15M
- Latest round: Seed (Aug 4, 2021)
- Investors on record: 2

## About

Home Biosciences SAS is a biotechnology firm specializing in innovative solutions for oncology and fibrotic diseases through proprietary technologies and AI-driven analysis.Founded in 2019 and headquartered in Paris, France, Home Biosciences SAS develops advanced biotech solutions aimed at addressing medical needs. The company has secured EUR 13.000 mn in Seed funding led by Redmile Group, which it aims to utilize for pipeline acceleration and team enhancement.Home Biosciences focuses on developing innovative biotech solutions through a capital-efficient and agile model. The company’s core offerings include a suite of proprietary technologies designed to address unmet medical needs in oncology and fibrotic diseases. One notable product is its single-cell-based technology, which utilizes AI-driven analysis on clinical specimens to generate functional profiles of tumors, thereby improving precision in cancer care. Additionally, Sequantrix, another initiative under Home Biosciences, leverages a vast human multi-modal, single-cell dataset to identify and validate novel therapeutic targets for fibrotic diseases. These products aim to enhance the understanding and treatment of complex medical conditions, making them invaluable to healthcare providers, academic institutions, and patients in markets like North America and Europe.Home Biosciences generates revenue primarily through partnerships and collaborations with research institutions and pharmaceutical companies, focusing on B2B transactions. The company's project teams, financed by Home Biosciences, engage in developing and bringing to market potential therapeutics, with funding structures in place to support ongoing operational needs. Transactions are structured around research and development agreements, with the company providing operational support and funding to project teams, ensuring a streamlined approach toward product development. Specific pricing plans and financial details related to their flagship products and services are aligned with the agreements made with partners, enhancing the potential for revenue generation as projects reach key milestones in development.In August 2021, Home Biosciences SAS raised EUR 13.000 mn in Seed funding led by new investor Redmile Group, with participation from Sofinnova Partners. The company plans to use this funding to accelerate the development of its therapeutic pipeline and strengthen its team. Future growth may include the launch of new products designed to tackle unmet medical needs in the oncology space, although specific release dates have not been disclosed. Home Biosciences is also looking to expand its market presence in North America and Europe.

## Funding rounds

- Seed, Aug 4, 2021, $15M — Sofinnova Partners, Redmile Group

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Seed